Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.53 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 6/20 | 0.40 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559608 | 0.84 | CYP11B1 (0.50) | AHRPDE7ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL18189576 | 0.81 | AHR (0.53) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL25066324 | 0.81 | AHR (0.56) | AHRPDE7ACMA1GRIA1CACNG8 | |
| SCHEMBL688899 | 0.81 | GRIA1 (0.42) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL7649298 | 0.78 | ALDH1A1 (0.47) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL5498437 | 0.78 | GRIA1 (0.41) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL20106765 | 0.78 | AHR (0.53) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL1163301 | 0.78 | AHR (0.53) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL20085519 | 0.77 | AHR (0.49) | AHRCMA1GRIA1CACNG8CACNG2 | |
| SCHEMBL22368226 | 0.76 | AHR (0.36) | AHRCMA1GRIA1CACNG8CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2015143376-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | AHR 2963/4885PDE7A 445/4885CMA1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.